Cargando…

Mesothelin Expression in Gastric Adenocarcinoma and Its Relation to Clinical Outcomes

BACKGROUND: Although surgical resection with chemotherapy is considered effective for patients with advanced gastric cancer, it remains the third leading cause of cancer-related death in South Korea. Several studies have reported that mesothelial markers including mesothelin, calretinin, and Wilms t...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Song-Hee, Joo, Mee, Kim, Hanseong, Chang, Sunhee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pathologists and the Korean Society for Cytopathology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357757/
https://www.ncbi.nlm.nih.gov/pubmed/28196410
http://dx.doi.org/10.4132/jptm.2016.11.18
_version_ 1782516096934346752
author Han, Song-Hee
Joo, Mee
Kim, Hanseong
Chang, Sunhee
author_facet Han, Song-Hee
Joo, Mee
Kim, Hanseong
Chang, Sunhee
author_sort Han, Song-Hee
collection PubMed
description BACKGROUND: Although surgical resection with chemotherapy is considered effective for patients with advanced gastric cancer, it remains the third leading cause of cancer-related death in South Korea. Several studies have reported that mesothelial markers including mesothelin, calretinin, and Wilms tumor protein 1 (WT1) were positive in variable carcinomas, associated with prognosis, and were evaluated as potential markers for targeted therapy. The aim of this study was to assess the immunohistochemical expression of mesothelial markers (mesothelin, calretinin, and WT1) in gastric adenocarcinoma and their relations to clinocopathological features and prognosis. METHODS: We evaluated calretinin, WT1, and mesothelin expression by immunohistochemical staining in 117 gastric adenocarcinomas. RESULTS: Mesothelin was positively stained in 30 cases (25.6%). Mesothelin expression was related to increased depth of invasion (p = .002), lymph node metastasis (p = .013), and presence of lymphovascular (p = .015) and perineural invasion (p = .004). Patients with mesothelin expression had significantly worse disease-free survival rate compared with that of nonmesothelin expression group (p = .024). Univariate analysis showed that mesothelin expression is related to short-term survival. None of the 117 gastric adenocarcinomas stained for calretinin or WT1. CONCLUSIONS: Mesothelin expression was associated with poor prognosis. Our results suggest that mesothelin-targeted therapy should be considered as an important therapeutic alternative for gastric adenocarcinoma patients with mesothelin expression.
format Online
Article
Text
id pubmed-5357757
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Korean Society of Pathologists and the Korean Society for Cytopathology
record_format MEDLINE/PubMed
spelling pubmed-53577572017-03-21 Mesothelin Expression in Gastric Adenocarcinoma and Its Relation to Clinical Outcomes Han, Song-Hee Joo, Mee Kim, Hanseong Chang, Sunhee J Pathol Transl Med Original Article BACKGROUND: Although surgical resection with chemotherapy is considered effective for patients with advanced gastric cancer, it remains the third leading cause of cancer-related death in South Korea. Several studies have reported that mesothelial markers including mesothelin, calretinin, and Wilms tumor protein 1 (WT1) were positive in variable carcinomas, associated with prognosis, and were evaluated as potential markers for targeted therapy. The aim of this study was to assess the immunohistochemical expression of mesothelial markers (mesothelin, calretinin, and WT1) in gastric adenocarcinoma and their relations to clinocopathological features and prognosis. METHODS: We evaluated calretinin, WT1, and mesothelin expression by immunohistochemical staining in 117 gastric adenocarcinomas. RESULTS: Mesothelin was positively stained in 30 cases (25.6%). Mesothelin expression was related to increased depth of invasion (p = .002), lymph node metastasis (p = .013), and presence of lymphovascular (p = .015) and perineural invasion (p = .004). Patients with mesothelin expression had significantly worse disease-free survival rate compared with that of nonmesothelin expression group (p = .024). Univariate analysis showed that mesothelin expression is related to short-term survival. None of the 117 gastric adenocarcinomas stained for calretinin or WT1. CONCLUSIONS: Mesothelin expression was associated with poor prognosis. Our results suggest that mesothelin-targeted therapy should be considered as an important therapeutic alternative for gastric adenocarcinoma patients with mesothelin expression. The Korean Society of Pathologists and the Korean Society for Cytopathology 2017-03 2017-02-15 /pmc/articles/PMC5357757/ /pubmed/28196410 http://dx.doi.org/10.4132/jptm.2016.11.18 Text en © 2017 The Korean Society of Pathologists/The Korean Society for Cytopathology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Han, Song-Hee
Joo, Mee
Kim, Hanseong
Chang, Sunhee
Mesothelin Expression in Gastric Adenocarcinoma and Its Relation to Clinical Outcomes
title Mesothelin Expression in Gastric Adenocarcinoma and Its Relation to Clinical Outcomes
title_full Mesothelin Expression in Gastric Adenocarcinoma and Its Relation to Clinical Outcomes
title_fullStr Mesothelin Expression in Gastric Adenocarcinoma and Its Relation to Clinical Outcomes
title_full_unstemmed Mesothelin Expression in Gastric Adenocarcinoma and Its Relation to Clinical Outcomes
title_short Mesothelin Expression in Gastric Adenocarcinoma and Its Relation to Clinical Outcomes
title_sort mesothelin expression in gastric adenocarcinoma and its relation to clinical outcomes
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357757/
https://www.ncbi.nlm.nih.gov/pubmed/28196410
http://dx.doi.org/10.4132/jptm.2016.11.18
work_keys_str_mv AT hansonghee mesothelinexpressioningastricadenocarcinomaanditsrelationtoclinicaloutcomes
AT joomee mesothelinexpressioningastricadenocarcinomaanditsrelationtoclinicaloutcomes
AT kimhanseong mesothelinexpressioningastricadenocarcinomaanditsrelationtoclinicaloutcomes
AT changsunhee mesothelinexpressioningastricadenocarcinomaanditsrelationtoclinicaloutcomes